Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Melanoma Res. 2018 Oct;28(5):390–397. doi: 10.1097/CMR.0000000000000474

Figure 2. The addition of IFN-alfa to MLN4924 treatment results in enhanced apoptosis of A375 BRAF(V600E) human melanoma cell line.

Figure 2

A) The A375 melanoma cell line was treated for 72 hours with 1200 nM MLN4924, 104 Units/mL IFN-α or 1 μM vemurafenib. Apoptosis levels were assessed by Annexin V/PI flow cytometry. B) A375 cells were treated with multiple concentrations of MLN4924 (0, 100, 1200 or 2000nM) or the combination of MLN4924 plus 104 Units/mL IFN-α or MLN4924 plus 1 μM vemurafenib and apoptosis was assessed. Data is presented as mean ± S.E.M. **p<0.005